Kopran Q2 FY27 Results: Consolidated Net Profit ₹4.39 Crore on Total Income of ₹212 Crore
- Earnings
- Pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Kopran (NSE: KOPRAN) reported total income of ₹211.89 crore and a net profit of ₹4.39 crore on a consolidated basis for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹87.98 crore and standalone net profit ₹6.29 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹211.89 crore, up 79.7% YoY and 35.8% QoQ
- Net profit and EPS: ₹4.39 crore; basic EPS ₹0.91, against a loss of ₹9.92 crore a year earlier
- Finance costs: ₹4.25 crore, up 103.3% YoY and 29.6% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹87.98 crore, up 106.0% YoY and 34.0% QoQ
- Net profit and EPS: ₹6.29 crore; basic EPS ₹1.30, against a loss of ₹3.99 crore a year earlier
- Finance costs: ₹1.39 crore, up 67.5% YoY and 12.1% QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 211.89 | 117.93 | +79.7% | 156.05 | +35.8% | |
| Revenue from operations | 211.27 | 117.90 | +79.2% | 155.97 | +35.5% |
| Other income | 0.62 | 0.03 | n/a | 0.08 | +695.9% |
| 4.39 | -9.92 | n/a | 6.70 | -34.5% | |
| Finance costs | 4.25 | 2.09 | +103.3% | 3.28 | +29.6% |
| Depreciation | 5.89 | 4.28 | +37.6% | 5.77 | +2.1% |
| Tax expense | 1.50 | -1.70 | n/a | 2.10 | -28.6% |
| Net profit margin | 2.07% | -8.41% | +10.48 pp | 4.29% | -2.22 pp |
| Tax as share of profit before tax | 25.5% | n/a | n/a | 23.9% | +1.60 pp |
| EPS, basic (₹) | 0.91 | n/a | n/a | 1.39 | -34.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit moved the other way to total income this quarter. Total income rose 35.8% on the quarter before, to ₹211.89 crore, while net profit fell 34.5%, to ₹4.39 crore from ₹6.70 crore. Tax expense rose to ₹1.50 crore from a credit of ₹1.70 crore a year earlier, and it was 25.5% of profit before tax of ₹5.89 crore.
Finance costs of ₹4.25 crore are 2.0% of total income this quarter, against 1.8% a year earlier on the year-ago figures of ₹2.09 crore and ₹117.93 crore. The filing does not explain the change in finance costs, and it does not give the reason for the foreign exchange loss of ₹2.19 crore shown in the statement.
Depreciation of ₹5.89 crore compares with ₹4.28 crore a year earlier. Other income of ₹0.62 crore is 10.6% of profit before tax, a small share of the quarter's result.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 87.98 | 42.71 | +106.0% | 65.67 | +34.0% | |
| Revenue from operations | 87.12 | 42.39 | +105.5% | 65.34 | +33.3% |
| Other income | 0.86 | 0.32 | +168.8% | 0.33 | +161.0% |
| 6.29 | -3.99 | n/a | 6.72 | -6.4% | |
| Finance costs | 1.39 | 0.83 | +67.5% | 1.24 | +12.1% |
| Depreciation | 1.39 | 1.16 | +19.8% | 1.35 | +3.0% |
| Tax expense | 2.12 | -0.88 | n/a | 2.06 | +2.9% |
| Net profit margin | 7.15% | -9.34% | +16.49 pp | 10.23% | -3.08 pp |
| Tax as share of profit before tax | 25.2% | n/a | n/a | 23.5% | +1.75 pp |
| EPS, basic (₹) | 1.30 | n/a | n/a | 1.39 | -6.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone revenue from operations rose 105.5% YoY, to ₹87.12 crore, which is slower than other income, up 168.8%. Other income is still a small part of the total, at 1.0% of total income.
Standalone net profit was ₹6.29 crore, down 6.4% from ₹6.72 crore in the previous quarter, while total income grew 34.0%. Tax was 25.2% of profit before tax of ₹8.41 crore. Finance costs of ₹1.39 crore are 1.6% of total income.
The consolidated net profit of ₹4.39 crore is ₹1.90 crore lower than the standalone figure of ₹6.29 crore. The consolidated review notes a subsidiary with total assets of ₹637.41 crore, reviewed by another auditor. Khandelwal Jain & Co. issued an unmodified review conclusion on both sets of results.
The company allotted 40,500 equity shares of ₹10 each during the quarter on exercise of employee stock options under the Kopran Employee Stock Option Plan 2023. The company operates primarily in pharmaceuticals and has no separate reportable segments.
Inference
The filing records a dividend paid of ₹14.49 crore in the half year ended 30 Sep 2026, on both consolidated and standalone bases, and paid-up equity share capital of ₹48.33 crore at a face value of ₹10 each.
The filing does not explain the swing from a year-ago loss to a profit this quarter, or the reason for the change in finance costs. Market value of ₹1,190 crore is Blacklitt's figure at the 03 Nov 2026 close and is not from the filing.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
